TTY Biopharm Company Limited Statistics
TTY Biopharm Company Limited (4105) Stock Statistics & Valuation Metrics
Total Valuation
TTY Biopharm Company Limited has a market cap or net worth of TWD 19.69B. The enterprise value is TWD 18.75B.
- Market Cap
- TWD 19.69B
- Enterprise Value
- TWD 18.75B
Share Statistics
TTY Biopharm Company Limited has 248,649,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 248,649,950
- Owned by Insiders
- ―
- Owned by Institutions
- 5.46%
Financial Efficiency
TTY Biopharm Company Limited’s return on equity (ROE) is 0.22 and return on invested capital (ROIC) is 13.37%.
- Return on Equity (ROE)
- 0.22
- Return on Assets (ROA)
- 0.14
- Return on Invested Capital (ROIC)
- 13.37%
- Return on Capital Employed (ROCE)
- 0.20
- Revenue Per Employee
- 11.50M
- Profits Per Employee
- 2.78M
- Employee Count
- 561
- Asset Turnover
- 0.57
- Inventory Turnover
- 1.97
Valuation Ratios
The current PE Ratio of TTY Biopharm Company Limited is 12.21. TTY Biopharm Company Limited’s PEG ratio is -1.66.
- PE Ratio
- 12.21
- PS Ratio
- 2.97
- PB Ratio
- 3.32
- Price to FCF
- 11.15
- Price to Operating Cash Flow
- 11.77
- PEG Ratio
- -1.66
Income Statement
In the last 12 months, TTY Biopharm Company Limited had revenue of 6.45B and earned 1.56B in profits. Earnings per share was 6.27.
- Revenue
- 6.45B
- Gross Profit
- 3.72B
- Operating Income
- 1.70B
- Pretax Income
- 2.13B
- Net Income
- 1.56B
- EBITDA
- 1.90B
- Earnings Per Share (EPS)
- 6.27
Cash Flow
In the last 12 months, operating cash flow was 1.96B and capital expenditures -147.50M, giving a free cash flow of 1.81B billion.
- Operating Cash Flow
- 1.96B
- Free Cash Flow
- 1.81B
- Free Cash Flow per Share
- 6.39
Dividends & Yields
TTY Biopharm Company Limited pays an annual dividend of ―, resulting in a dividend yield of 5.68%
- Dividend Per Share
- ―
- Dividend Yield
- 5.68%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 8.87%
- Earnings Yield
- 7.51%
Stock Price Statistics
- Beta
- 0.15
- 52-Week Price Change
- 4.31%
- 50-Day Moving Average
- 79.31
- 200-Day Moving Average
- 76.86
- Relative Strength Index (RSI)
- 45.35
- Average Volume (3m)
- 589.69K
Important Dates
TTY Biopharm Company Limited upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 30, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
TTY Biopharm Company Limited as a current ratio of 2.28, with Debt / Equity ratio of 16.93%
- Current Ratio
- 2.28
- Quick Ratio
- 1.75
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- -0.68
- Interest Coverage Ratio
- 44.08
Taxes
In the past 12 months, TTY Biopharm Company Limited has paid 470.47M in taxes.
- Income Tax
- 470.47M
- Effective Tax Rate
- 0.22
Enterprise Valuation
TTY Biopharm Company Limited EV to EBITDA ratio is 8.36, with an EV/FCF ratio of 10.82.
- EV to Sales
- 2.88
- EV to EBITDA
- 8.36
- EV to Free Cash Flow
- 10.82
- EV to Operating Cash Flow
- 10.01
Balance Sheet
TTY Biopharm Company Limited has TWD 2.94B in cash and marketable securities with TWD 2.11B in debt, giving a net cash position of TWD 832.99M billion.
- Cash & Marketable Securities
- TWD 2.94B
- Total Debt
- TWD 2.11B
- Net Cash
- TWD 832.99M
- Net Cash Per Share
- TWD 3.35
- Tangible Book Value Per Share
- TWD 27.05
Margins
Gross margin is 58.07%, with operating margin of 32.89%, and net profit margin of 25.75%.
- Gross Margin
- 58.07%
- Operating Margin
- 32.89%
- Pretax Margin
- 33.07%
- Net Profit Margin
- 25.75%
- EBITDA Margin
- 34.48%
- EBIT Margin
- 32.89%
Analyst Forecast
The average price target for TTY Biopharm Company Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 4.54%
- EPS Growth Forecast
- -7.38%
